Totally implantable vascular access devices (TIVADs) are a safe and effective method of providing long-term intravenous therapy for patients with CF and can usually be left in situ for up to 2 years. Special needles are used to access ports and this should only be done by trained staff with strict asepsis.
Overall complication rates of 12-20% have been reported: the most common complications are [18]: